P38 MAPK Controls Prothrombin Expression by Regulated RNA 3' End Processing

Molecular Cell

Volumn 41, Issue 3, 2011, Pages 298-310

  Danckwardt, Sven ^a   Gantzert, Anne Susan ^a   Macher Goeppinger, Stephan ^a   Probst, Hans Christian ^b   Gentzel, Marc ^c,f   Wilm, Matthias ^d,f   Gröne, Hermann Josef ^e   Schirmacher, Peter ^a   Hentze, Matthias W ^a,f   Kulozik, Andreas E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTHROMBIN; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; RNA BINDING PROTEIN FBP2; RNA BINDING PROTEIN FBP3; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BLOOD CLOTTING; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; INFLAMMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA PROCESSING; STRESS; TRANSCRIPTION REGULATION;

ADENOSINE; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MICE; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERS; PROTEIN BINDING; PROTHROMBIN; RIBONUCLEOPROTEINS; RNA; RNA 3' END PROCESSING; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79251587477     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2010.12.032     Document Type: Article

References (67)

1. Barabino S.M., Keller W. Last but not least: regulated poly(A) tail formation. Cell 1999, 99:9-11.
2. Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293:715-722.
3. Boccaccio C., Comoglio P.M. A functional role for hemostasis in early cancer development. Cancer Res. 2005, 65:8579-8582.
4. Boven L.A., Vergnolle N., Henry S.D., Silva C., Imai Y., Holden J., Warren K., Hollenberg M.D., Power C. Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J. Immunol. 2003, 170:2638-2646.
5. Briata P., Forcales S.V., Ponassi M., Corte G., Chen C.Y., Karin M., Puri P.L., Gherzi R. p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol. Cell 2005, 20:891-903.
6. Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., Oyama R., Ravasi T., Lenhard B., Wells C., et al. The transcriptional landscape of the mammalian genome. Science 2005, 309:1559-1563. FANTOM Consortium, RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group)RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group).
7. Chapman J. Thrombin in inflammatory brain diseases. Autoimmun. Rev. 2006, 5:528-531.
8. Chen C.Y., Xu N., Shyu A.B. mRNA decay mediated by two distinct AU-rich elements from c-fos and granulocyte-macrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation. Mol. Cell. Biol. 1995, 15:5777-5788.
9. Citron B.A., Smirnova I.V., Arnold P.M., Festoff B.W. Upregulation of neurotoxic serine proteases, prothrombin, and protease-activated receptor 1 early after spinal cord injury. J. Neurotrauma 2000, 17:1191-1203.
10. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
11. Danckwardt S., Gehring N.H., Neu-Yilik G., Hundsdoerfer P., Pforsich M., Frede U., Hentze M.W., Kulozik A.E. The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 2004, 104:428-435.
12. Danckwardt S., Kaufmann I., Gentzel M., Foerstner K.U., Gantzert A.S., Gehring N.H., Neu-Yilik G., Bork P., Keller W., Wilm M., et al. Splicing factors stimulate polyadenylation via USEs at non-canonical 3' end formation signals. EMBO J. 2007, 26:2658-2669.
13. Danckwardt S., Hentze M.W., Kulozik A.E. 3' end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J. 2008, 27:482-498.
14. Dihanich M., Kaser M., Reinhard E., Cunningham D., Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 1991, 6:575-581.
15. Edwalds-Gilbert G., Veraldi K.L., Milcarek C. Alternative poly(A) site selection in complex transcription units: means to an end?. Nucleic Acids Res. 1997, 25:2547-2561.
16. Even-Ram S., Uziely B., Cohen P., Grisaru-Granovsky S., Maoz M., Ginzburg Y., Reich R., Vlodavsky I., Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 1998, 4:909-914.
17. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
18. Gehring N.H., Frede U., Neu-Yilik G., Hundsdoerfer P., Vetter B., Hentze M.W., Kulozik A.E. Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat. Genet. 2001, 28:389-392.
19. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
20. Gingrich M.B., Junge C.E., Lyuboslavsky P., Traynelis S.F. Potentiation of NMDA receptor function by the serine protease thrombin. J. Neurosci. 2000, 20:4582-4595.
21. Hall-Pogar T., Liang S., Hague L.K., Lutz C.S. Specific trans-acting proteins interact with auxiliary RNA polyadenylation elements in the COX-2 3'-UTR. RNA 2007, 13:1103-1115.
22. Harrold S., Genovese C., Kobrin B., Morrison S.L., Milcarek C. A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors. Anal. Biochem. 1991, 198:19-29.
23. Hu L., Roth J.M., Brooks P., Luty J., Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res. 2008, 68. 4666-467.
24. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
25. Ji Z., Tian B. Reprogramming of 3' untranslated regions of mRNAs by alternative polyadenylation in generation of pluripotent stem cells from different cell types. PLoS ONE 2009, 4:e8419.
26. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
27. Kazerouninia A., Ngo B., Martinson H.G. Poly(A) signal-dependent degradation of unprocessed nascent transcripts accompanies poly(A) signal-dependent transcriptional pausing in vitro. RNA 2010, 16:197-210. Published online November 19, 2009.
28. Kim S., Buonanno A., Nelson P.G. Regulation of prothrombin, thrombin receptor, and protease nexin-1 expression during development and after denervation in muscle. J. Neurosci. Res. 1998, 53:304-311.
29. Kuderer N.M., Ortel T.L., Francis C.W. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J. Clin. Oncol. 2009, 27:4902-4911.
30. Lane D.A., Grant P.J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000, 95:1517-1532.
31. Levi M., Ten Cate H. Disseminated intravascular coagulation. N. Engl. J. Med. 1999, 341:586-592.
32. Licatalosi D.D., Mele A., Fak J.J., Ule J., Kayikci M., Chi S.W., Clark T.A., Schweitzer A.C., Blume J.E., Wang X., et al. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature 2008, 456:464-469.
33. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
34. Lutz C.S. Alternative polyadenylation: a twist on mRNA 3' end formation. ACS Chem. Biol. 2008, 3:609-617.
35. Mahadevan L.C., Edwards D.R. Signalling and superinduction. Nature 1991, 349:747-748.
36. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
37. Mayr C., Bartel D.P. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009, 138:673-684.
38. Miller G.J., Bauer K.A., Howarth D.J., Cooper J.A., Humphries S.E., Rosenberg R.D. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J. Thromb. Haemost. 2004, 2:2107-2114.
39. Millevoi S., Decorsière A., Loulergue C., Iacovoni J., Bernat S., Antoniou M., Vagner S. A physical and functional link between splicing factors promotes pre-mRNA 3' end processing. Nucleic Acids Res. 2009, 37:4672-4683.
40. Moreira A., Takagaki Y., Brackenridge S., Wollerton M., Manley J.L., Proudfoot N.J. The upstream sequence element of the C2 complement poly(A) signal activates mRNA 3' end formation by two distinct mechanisms. Genes Dev. 1998, 12:2522-2534.
41. Murakami H., Okazaki M., Amagasa H., Oguchi K. Increase in hepatic mRNA expression of coagulant factors in type 2 diabetic model mice. Thromb. Res. 2003, 111:81-87.
42. Nierodzik M.L., Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10:355-362.
43. Palumbo J.S., Talmage K.E., Massari J.V., La Jeunesse C.M., Flick M.J., Kombrinck K.W., Hu Z., Barney K.A., Degen J.L. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007, 110:133-141.
44. Pawlicki J.M., Steitz J.A. Nuclear networking fashions pre-messenger RNA and primary microRNA transcripts for function. Trends Cell Biol. 2010, 20:52-61. Published online December 11, 2009.
45. Petralia G.A., Lemoine N.R., Kakkar A.K. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat. Clin. Pract. Oncol. 2005, 2:356-363.
46. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698-3703.
47. Proudfoot N.J., Furger A., Dye M.J. Integrating mRNA processing with transcription. Cell 2002, 108:501-512.
48. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., Davis R.J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 1995, 270:7420-7426.
49. Riek-Burchardt M., Striggow F., Henrich-Noack P., Reiser G., Reymann K.G. Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. Neurosci. Lett. 2002, 329:181-184.
50. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 2008, 8:776-787.
51. Sandberg R., Neilson J.R., Sarma A., Sharp P.A., Burge C.B. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science 2008, 320:1643-1647.
52. Schulman S., Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N. Engl. J. Med. 2000, 342:1953-1958.
53. Shell S.A., Hesse C., Morris S.M., Milcarek C. Elevated levels of the 64-kDa cleavage stimulatory factor (CstF-64) in lipopolysaccharide-stimulated macrophages influence gene expression and induce alternative poly(A) site selection. J. Biol. Chem. 2005, 280:39950-39961.
54. Shyu A.-B., Wilkinson M.F. The double lives of shuttling mRNA binding proteins. Cell 2000, 102:135-138.
55. Shyu A.B., Greenberg M.E., Belasco J.G. The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev. 1989, 3:60-72.
56. Sullivan K.D., Steiniger M., Marzluff W.F. A core complex of CPSF73, CPSF100, and Symplekin may form two different cleavage factors for processing of poly(A) and histone mRNAs. Mol. Cell 2009, 34:322-332.
57. Takagaki Y., Seipelt R.L., Peterson M.L., Manley J.L. The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. Cell 1996, 87:941-952.
58. Tian B., Hu J., Zhang H., Lutz C.S. A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res. 2005, 33:201-212.
59. VanLandingham J.W., Cekic M., Cutler S.M., Hoffman S.W., Washington E.R., Johnson S.J., Miller D., Stein D.G. Progesterone and its metabolite allopregnanolone differentially regulate hemostatic proteins after traumatic brain injury. J. Cereb. Blood Flow Metab. 2008, 28:1786-1794.
60. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
61. Wang E.T., Sandberg R., Luo S., Khrebtukova I., Zhang L., Mayr C., Kingsmore S.F., Schroth G.P., Burge C.B. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476.
62. Wilhelm B.T., Marguerat S., Watt S., Schubert F., Wood V., Goodhead I., Penkett C.J., Rogers J., Bähler J. Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. Nature 2008, 453:1239-1243.
63. Wilusz C.J., Wilusz J. Bringing the role of mRNA decay in the control of gene expression into focus. Trends Genet. 2004, 20:491-497.
64. Xi G., Reiser G., Keep R.F. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?. J. Neurochem. 2003, 84:3-9.
65. Xiang K., Nagaike T., Xiang S., Kilic T., Beh M.M., Manley J.L., Tong L. Crystal structure of the human symplekin-Ssu72-CTD phosphopeptide complex. Nature 2010, 467:729-733.
66. Yin X., Wright J., Wall T., Grammas P. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am. J. Pathol. 2010, 176:1600-1606.
67. Zoubine M.N., Ma J.Y., Smirnova I.V., Citron B.A., Festoff B.W. A molecular mechanism for synapse elimination: novel inhibition of locally generated thrombin delays synapse loss in neonatal mouse muscle. Dev. Biol. 1996, 179:447-457.